A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Recruiting now · Phase 1/Phase 2
Conditions studied: Solid Malignancies
In brief
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
Key facts
- Study ID
- NCT06600789
- Run by
- Carrick Therapeutics Limited
- People needed
- 50
- Starts
- 2024-08-16
- Expected to finish
- 2026-05-22
- Last updated by the study team
- 2025-11-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research site 03 — Dallas, Texas, United States (enrolling)
- Research site 01 — San Antonio, Texas, United States (enrolling)
- Research site 02 — Fairfax, Virginia, United States (enrolling)
- Research site 05 — Manchester, United Kingdom (enrolling)
- Research site 04 — Oxford, United Kingdom (enrolling)
- Research site 06 — Sutton, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.